Edition:
United States

OncoGenex Pharmaceuticals Inc (OGXI.OQ)

OGXI.OQ on NASDAQ Stock Exchange Capital Market

0.58USD
17 Jan 2017
Change (% chg)

-- (--)
Prev Close
$0.58
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
115,176
52-wk High
$1.41
52-wk Low
$0.33

Latest Key Developments (Source: Significant Developments)

Oncogenex Pharmaceuticals and Achieve Life Science announce definitive merger agreement
Thursday, 5 Jan 2017 04:30pm EST 

Oncogenex Pharmaceuticals Inc : Oncogenex Pharmaceuticals Inc and Achieve Life Science, Inc announce definitive merger agreement . Oncogenex - upon completion of proposed merger, achieve's equity holders are expected to own 75 pct of combined company's outstanding shares . Oncogenex Pharmaceuticals Inc - combined company's executive management team will be led by Rick Stewart, chairman of Achieve . Oncogenex Pharmaceuticals - expected to distribute to its stockholders contingent value rights (CVRS) for 80 pct of any net proceeds of certain payments . Oncogenex Pharmaceuticals Inc - board of directors of combined company is expected to consist of seven members . Following completion of merger, Oncogenex Pharmaceuticals Inc ill be renamed Achieve Life Sciences Inc . Oncogenex - after completion, current stockholders of oncogenex are expected to own remaining 25 pct of combined company's outstanding shares . Oncogenex Pharmaceuticals Inc - "efforts will continue to establish a strategic partnership to further development of apatorsen" .Oncogenex Pharmaceuticals Inc - transaction has been approved unanimously by boards of directors of both companies.  Full Article

Oncogenex Pharmaceuticals says committed to further reduction in workforce
Thursday, 17 Nov 2016 04:17pm EST 

Oncogenex Pharmaceuticals Inc : Will eliminate 5 positions and estimates that will incur about $750,000 in cash expenditures as a result . On Nov 14, co committed to further reduction in workforce in order to preserve company's resources .Expects workforce reduction to be substantially complete in Q4 of 2016 - SEC filing.  Full Article

Oncogenex Pharmaceuticals reports Q3 loss per share $0.12
Thursday, 10 Nov 2016 04:01pm EST 

Oncogenex Pharmaceuticals Inc - : Oncogenex Pharmaceuticals Inc reports financial results for third quarter 2016 . Qtrly loss per share $0.12 .Qtrly revenue $3.8 million versus $3.1 million.  Full Article

Oncogenex's Phase 3 trial of Custirsen in men did not meet primary endpoint
Tuesday, 16 Aug 2016 07:00am EDT 

Oncogenex Pharmaceuticals Inc : Oncogenex announces results from the phase 3 affinity trial of custirsen in men with metastatic castrate-resistant prostate cancer . To initiate discussions with U.S. Food and drug administration to evaluate options related to an early analysis of phase 3 enspirit trial . Trial did not meet primary endpoint . Adverse events were consistent with those observed in previous trials of custirsen in metastatic crpc .Engaged MTS Health Partners, Lp as its advisor to assist with exploration of strategic alternatives.  Full Article

Oncogenex Pharma Q2 revenue $2.1 million vs est $1.2 million
Thursday, 4 Aug 2016 04:01pm EDT 

Oncogenex Pharmaceuticals Inc : Oncogenex pharmaceuticals, inc. Reports financial results for second quarter 2016 . Q2 revenue $2.1 million .Q2 revenue view $1.2 million -- Thomson Reuters I/B/E/S.  Full Article

Oncogenex Pharmaceuticals qtrly loss per share $0.12
Thursday, 12 May 2016 04:15pm EDT 

Oncogenex Pharmaceuticals Inc : Qtrly loss per share $0.12 . Oncogenex pharmaceuticals, inc. Reports financial results for first quarter 2016 . Q1 revenue $2.9 million .Q1 revenue view $4.1 million -- Thomson Reuters I/B/E/S.  Full Article

OncoGenex Pharmaceuticals Inc Presents Additional Phase 3 SYNERGY Analyses Showing Custirsen Significantly Reduced Serum Clusterin Levels in Metastatic Prostate Cancer Patients
Monday, 28 Sep 2015 01:00am EDT 

OncoGenex Pharmaceuticals Inc:Press release - OncoGenex presents additional phase 3 synergy analyses showing custirsen significantly reduced serum clusterin levels in metastatic prostate cancer patients; low levels correlate with improved survival in those at increased risk for poor o.Working closely with investigators and regulatory agencies to determine next steps as we collect more evidence of apatorsen's activity.Completion of enrollment in the phase 2 borealis-2 bladder cancer trial is expected to occur by the end of 2015.Custirsen has fast track designation by the U.S. food and drug administration for metastatic crpc and non-small cell lung cancer.  Full Article

OncoGenex announces phase 2 rainier results in previously untreated metastatic pancreatic cancer
Wednesday, 23 Sep 2015 07:00am EDT 

OncoGenex Pharmaceuticals Inc:Announces initial results from the Phase 2 Rainier(tm) study evaluating apatorsen in combination with ABRAXANE and gemcitabine compared to ABRAXANE and gemcitabine alone in patients with untreated metastatic pancreatic cancer.Says the addition of apatorsen to ABRAXANE and gemcitabine did not demonstrate a survival benefit compared to ABRAXANE and gemcitabine alone.Says the study was sponsored and conducted by Sarah Cannon Research Institute (SCRI) and further results will be presented by SCRI at a future medical meeting.  Full Article

FDA agrees with Oncogenex Pharmaceuticals Inc' phase 3 affinity protocol amendment
Wednesday, 10 Jun 2015 07:00am EDT 

Oncogenex Pharmaceuticals Inc:FDA agrees with oncogenex' phase 3 affinity protocol amendment.Says co-primary survival endpoint included for a prospectively-defined poor prognosis subpopulation.FDA agreed to the company's proposed amendment to the phase 3 affinity protocol and statistical analysis plan.Initiated review with European medicines agency for amendment to phase 3 affinity protocol,statistical analysis plan.Co,fda agreed interim analysis will occur for itt population when final analysis for the poor prognosis subpopulation occurs.Expects to have completed review with European medicines agency in the second half of 2015.  Full Article

OncoGenex Pharmaceuticals Inc gives data from borealis-1(TM) trial showing clinical benefit with apatorsen in metastatic bladder cancer
Monday, 1 Jun 2015 10:45am EDT 

OncoGenex Pharmaceuticals Inc:Says overall treatment was well tolerated.  Full Article

BRIEF-Oncogenex Pharmaceuticals says committed to further reduction in workforce

* Will eliminate 5 positions and estimates that will incur about $750,000 in cash expenditures as a result